|
Click Here for a detailed listing of studies,
formatted as a .pdf
A Randomized Multicenter, Double-Blind, Placebo-Controlled
Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy
plus Trastuzumab plus Pertuzumab as adjuvant Therapy in Patients with
Operable HER2-positive Primary Breast Cancer
LUX: An open label, randomised phase III trial of BIBW
2992 and vinorelbine versus trastuzumab and vinorelbine in patients with
metastatic HER2-overexpressing breast cancer failing one prior trastuzumab
treatment
AMG 162: A Randomized, Double-Blind, Placebo-Controlled,
Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women
with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
PT-304: Prediction of Response to Neoadjuvant Chemotherapy
in Women with Operable Breast Cancer
Lumpectomy and Brachytherapy as Salvage Treatment
for Local Recurrences Following Breast Conservative Therapy
Investigating Radiation Therapy: The
Accelerated RT Trial
Mammary Ductoscopy
and Intraductal Biopsy for Women at High Risk for Developing Breast Cancer,
for Women Presenting with Spontaneous Nipple Discharge, and for Women
Diagnosed with Breast Cancer Undergoing Surgery to the Contralateral Breast
A Phase 2 Randomized, Double-Blind, Placebo-Controlled
Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI
as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma
that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing
Regimen.
A Phase III Trial Evaluating the Addition of Trastuzumab
to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma.
A Phase II Study For Patients With Advanced Rectal
Cancer Using Pre-Operative High Dose Rate Brachytherapy + Folfox Chemotherapy
A Phase III Trial of 6 Versus 12 Treatments
of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected
Stage III Colon Cancer.
A Phase III Randomized, Double-Blind Trial of Chemoembolization
with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC)
in Patients with and without Vascular Invasion.
RTOG 0436: A Phase III Trials Evaluating the Addition
of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with
Esophageal Cancer Who Are Treated Without Surgery
Phase II Trial of Combination Pemetrexed
(Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent
Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
GOG-0263: RANDOMIZED PHASE III CLINICAL TRIAL
OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE
I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC
LYMPHADENECTOMY.
Phase 1/2 Study of PX-866 and Docetaxel in Patients
with Solid Tumors
A Phase 2b, Multi-center, Randomized,
Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety
of Three Different Doses of SCV‑07 in Attenuating Oral Mucositis
in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy
and Radiotherapy.
Prospective Evaluation of Unilateral/Ipsilateral
Neck Irradiation Combined with Amifostine in Selected Patients with Squamous
Cell Carcinoma of the Head and Neck Who are Managed by Radiation Therapy.
RTOG 0920: A Phase III Study of Postoperative
Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head
and Neck Cancer
A phase I trial of adjuvant chemotherapy using
cetuximab (c) and docetaxel (t) for N2b-3 HNSCC patients with positive
pathologic residual neck diseases after concurrent chemoradiation (CRT)
A Phase III Randomized Trial of Chemotherapy
With or Without Bevacizumab in Patients with Recurrent or Metastatic Head
and Neck Cancer
TTP: Phase II study of danazol with plasma exchange
and steroids for the treatment of thrombotic thrombocytopenic purpura
Surgical Cytoreduction Followed
by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for
the Management of Disseminated Pleural Malignancies
Phase 1/2 Study of PX-866 and Docetaxel in
Patients with Solid Tumors
Lilly JVBA (IMCL CP12-1027): A Randomized, Double-Blind,
Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo
in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease
Progression after One Prior Platinum-Based Therapy
RTOG 0813: Seamless Phase I/II Study of Stereotactic
Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small
Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Lymphoma
Calistoga: A Phase 2 Study to Assess
the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin
Lymphoma Refractory to Rituximab and Alkylating Agents.
SWOG 0816: A Phase II Trial of Response Adapted
Therapy of Stage III-lV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
An Open-Label, Randomized, Phase 2 Study
to Assess the Effectiveness of
RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal
Center B-Cell-like Diffuse Large B-Cell Lymphoma
Pancreatic
A Phase 2 Randomized, Double-Blinded,
Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624
Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic
Adenocarcinoma
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment
of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Prostate
A Phase 1b/2 Study Of Docetaxel And Prednisone,
With Or Without ISIS 183750 (an eIF4E Inhibitor), In Patients With Castrate-Resistant
Prostate Cancer
ECOG 2809: Androgen Receptor Modulation:
Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients
With Rising PSA at High-Risk of Progression After Primary Therapy
Analysis of circulating tumor cells
in prostate cancer. Predicting response to taxanes: A Pilot Study
Image-Guided Intensity-Modulated Radiotherapy (IG-IMRT)
for Prostate Cancer
Renal
Proleukin® Observational Registry to Evaluate
the Treatment Patterns and Clinical Response in Malignancy
A Randomized Phase II Trial of Sunitinib/Gemcitabine
or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
A Randomized Phase II Study to Determine the
Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic
Renal Cell Carcinoma
Phase I Trial of Stereotactic Body Radiotherapy
(SBRT) of the Primary Tumor in Renal Cell Carcinoma (RCC)
A randomized, double-blind, placebo-controlled
phase III study to evaluate the efficacy and safety of pazopanib as adjuvant
therapy for subjects with localized or locally advanced RCC following
nephrectomy
Skin
Multicenter, non-randomized, prospective study for
the treatment of non-melanoma skin cancer (squamous cell cancer and basal
cell cancer) using Xoft Axxent Electronic Brachytherapy Treatment System
as the primary treatment for NMSC
|
